Loading...
This has been an exciting year for us, as we have changed our name to NEJM Journal Watch Oncology and Hematology. We remain devoted to providing clinicians with the information they need to give their patients the best care — and, as part of NEJM Group, we are now poised to do that better than ever. We are working to provide you with richer content, enhanced graphics, and a new website. Of course, our primary goal of serving you has not changed: We seek to provide you with the most current, clinically relevant information to assist you in your practice.
This year, our list of the NEJM Journal Watch Oncology and Hematology top 10 Stories covers a broad range of topics, including benign and malignant hematology and cancers of the breast, lung, prostate, and pancreas. These summaries highlight our goal of identifying the most clinically relevant manuscripts and highlighting their key points, limitations, and applications. We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.
Our Oncology and Hematology Top Stories of 2013 are:
Ponatinib for Philadelphia Chromosome–Positive Leukemias
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Breast Cancer
Nab-Paclitaxel plus Gemcitabine Improves Survival in Pancreatic Cancer
Management of Superficial Venous Thrombosis
Smoldering Multiple Myeloma: Dousing the Fire?
Ibrutinib for Mantle-Cell Lymphoma
Curing Acute Promyelocytic Leukemia Without Chemotherapy
Dual-Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer
Late Effects of Interventions for Localized Prostate Cancer
Abiraterone Effective for Chemotherapy-Naive Prostate Cancer Patients